Cargando…

Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up!

Detalles Bibliográficos
Autores principales:	Midtvedt, Karsten, Tran, Trung, Parker, Krystina, Marti, Hans-Peter, Stenehjem, Aud-E., Gøransson, Lasse Gunnar, Mørkve Soldal, Kari, Madsen, Camilla, Smedbråten, Julia, Vaage, Eline Benno, Lund-Johansen, Fridtjof, Åsberg, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294835/ https://www.ncbi.nlm.nih.gov/pubmed/34132229 http://dx.doi.org/10.1097/TP.0000000000003856

Ejemplares similares

Humoral Response After 6 or More Successive Doses of SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients—Should We Keep Vaccinating?
por: Åsberg, Anders, et al.
Publicado: (2023)

Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study
por: Hovd, Markus, et al.
Publicado: (2023)

Trends in seroprevalence of SARS‐CoV‐2 and infection fatality rate in the Norwegian population through the first year of the COVID‐19 pandemic
por: Tunheim, Gro, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

BNT-162b1: Stevens-Johnson syndrome: case report
Publicado: (2021)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients
por: Attias, Philippe, et al.
Publicado: (2021)

Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
por: Roca, B, et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
por: Bauernfeind, Stilla, et al.
Publicado: (2021)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Aseptic meningitis after BNT-162b2 COVID-19 vaccination
por: Chan, Amanda CY., et al.
Publicado: (2021)

Reactive arthritis following COVID-19 vaccination with BNT162b2
por: Lebowitz, Emily, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain
por: Pardo-Seco, Jacobo, et al.
Publicado: (2022)

Myocarditis after BNT162b2 vaccination in a healthy male
por: Watkins, Kevin, et al.
Publicado: (2021)

BNT-162b1/clobetasol: Pernio and lack of efficacy: case report
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tti6m3caad8ifna8phj2mt5dpb